

## 2022 Formulary Addendum

Below is a list formulary changes for the benefit year 2022. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2022 downloadable formulary on the **Care N' Care (HMO/PPO)** website.

For a complete list of drugs covered by **Care N' Care (HMO/PPO)**, please visit our Website at [www.cnchealthplan.com](http://www.cnchealthplan.com) or call the Customer Experience Team at 1-877-374-7993 or, for TTY users, 711, October 1 – March 31, seven (7) days a week/8 a.m. – 8 p.m. (CST), or April 1 – September 30, Monday through Friday, 8 a.m. – 8 p.m. (CST).

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

| 2022 FORMULARY CHANGES                                    |                   |                 |                       |                                           |
|-----------------------------------------------------------|-------------------|-----------------|-----------------------|-------------------------------------------|
| Drug Name                                                 | Current Drug Tier | New Drug Tier   | Reason For Change     | Alternative Drug, Alternative Drug Tier   |
| <b>EFFECTIVE 01/01/2022</b>                               |                   |                 |                       |                                           |
| Ayvakit Tablet 25 MG Oral                                 | NF                | 5 + QL 30 + PA2 | Formulary Enhancement | N/A                                       |
| Ayvakit Tablet 50 MG Oral                                 | NF                | 5 + QL 30 + PA2 | Formulary Enhancement | N/A                                       |
| chlorproMAZINE HCl Concentrate 100 MG/ML Oral             | NF                | 2               | Formulary Enhancement | N/A                                       |
| chlorproMAZINE HCl Concentrate 30 MG/ML Oral              | NF                | 2               | Formulary Enhancement | N/A                                       |
| Clovique Capsule 250 MG Oral                              | 5 + PA1           | NF              | CMS Required Deletion | N/A                                       |
| Dupixent Solution Pen-Injector 200 MG/1.14ML Subcutaneous | NF                | 5 + PA1         | Formulary Enhancement | N/A                                       |
| Etravirine Tablet 100 MG Oral                             | NF                | 5 + QL 120      | Formulary Enhancement | N/A                                       |
| Etravirine Tablet 200 MG Oral                             | NF                | 5 + QL 60       | Formulary Enhancement | N/A                                       |
| Intelence Tablet 100 MG Oral                              | 5 + QL 120        | NF              | Formulary Update      | etravirine tablet 100 mg oral, 5 + QL 120 |

## 2022 Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

| 2022 FORMULARY CHANGES                                         |                   |                       |                       |                                                       |
|----------------------------------------------------------------|-------------------|-----------------------|-----------------------|-------------------------------------------------------|
| Drug Name                                                      | Current Drug Tier | New Drug Tier         | Reason For Change     | Alternative Drug, Alternative Drug Tier               |
| Intelence Tablet 200 MG Oral                                   | 5 + QL 60         | NF                    | Formulary Update      | etravirine tablet 200 mg oral, 5 + QL 60              |
| Kaletra Tablet 100-25 MG Oral                                  | 3 + QL 300        | NF                    | Formulary Update      | lopinavir-ritonavir tablet 100-25 mg oral, 3 + QL 300 |
| Kaletra Tablet 200-50 MG Oral                                  | 3 + QL 120        | NF                    | Formulary Update      | lopinavir-ritonavir tablet 200-50 mg oral, 3 + QL 120 |
| Kloxxado Liquid 8 MG/0.1ML Nasal                               | NF                | 3                     | Formulary Enhancement | N/A                                                   |
| Lopinavir-Ritonavir Tablet 100-25 MG Oral                      | NF                | 3 + QL 300            | Formulary Enhancement | N/A                                                   |
| Lopinavir-Ritonavir Tablet 200-50 MG Oral                      | NF                | 3 + QL 120            | Formulary Enhancement | N/A                                                   |
| Lumakras Tablet 120 MG Oral                                    | NF                | 5 + QL 240 + PA2 + LA | Formulary Enhancement | N/A                                                   |
| Potassium Chloride Crys ER Tablet Extended Release 15 MEQ Oral | NF                | 1                     | Formulary Enhancement | N/A                                                   |
| Rezurock Tablet 200 MG Oral                                    | NF                | 5 + PA1 + LA          | Formulary Enhancement | N/A                                                   |
| SUNItinib Malate Capsule 12.5 MG Oral                          | NF                | 5 + PA2               | Formulary Enhancement | N/A                                                   |
| SUNItinib Malate Capsule 25 MG Oral                            | NF                | 5 + PA2               | Formulary Enhancement | N/A                                                   |
| SUNItinib Malate Capsule 37.5 MG Oral                          | NF                | 5 + PA2               | Formulary Enhancement | N/A                                                   |
| SUNItinib Malate Capsule 50 MG Oral                            | NF                | 5 + PA2               | Formulary Enhancement | N/A                                                   |
| Sutent Capsule 12.5 MG Oral                                    | 5 + PA2           | NF                    | Formulary Update      | sunitinib malate capsule 12.5 mg oral, 5 + PA2        |

2022

## Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

| 2022 FORMULARY CHANGES                                          |                   |               |                       |                                                |
|-----------------------------------------------------------------|-------------------|---------------|-----------------------|------------------------------------------------|
| Drug Name                                                       | Current Drug Tier | New Drug Tier | Reason For Change     | Alternative Drug, Alternative Drug Tier        |
| Sutent Capsule 25 MG Oral                                       | 5 + PA2           | NF            | Formulary Update      | sunitinib malate capsule 25 mg oral, 5 + PA2   |
| Sutent Capsule 37.5 MG Oral                                     | 5 + PA2           | NF            | Formulary Update      | sunitinib malate capsule 37.5 mg oral, 5 + PA2 |
| Sutent Capsule 50 MG Oral                                       | 5 + PA2           | NF            | Formulary Update      | sunitinib malate capsule 50 mg oral, 5 + PA2   |
| Theophylline ER Tablet Extended Release 12 Hour 450 MG Oral     | NF                | 1             | Formulary Enhancement | N/A                                            |
| Tirosint-SOL Solution 37.5 MCG/ML Oral                          | NF                | 4             | Formulary Enhancement | N/A                                            |
| Tirosint-SOL Solution 44 MCG/ML Oral                            | NF                | 4             | Formulary Enhancement | N/A                                            |
| Tirosint-SOL Solution 62.5 MCG/ML Oral                          | NF                | 4             | Formulary Enhancement | N/A                                            |
| Triakta Tablet Therapy Pack 50-25-37.5 & 75 MG Oral             | NF                | 5 + PA1 + LA  | Formulary Enhancement | N/A                                            |
| TriLyte Solution Reconstituted 420 GM Oral                      | 1                 | NF            | CMS Required Deletion | N/A                                            |
| Xcopri (250 MG Daily Dose) Tablet Therapy Pack 50 & 200 MG Oral | 4                 | NF            | CMS Required Deletion | N/A                                            |
| Xofluza (40 MG Dose) Tablet Therapy Pack 1 x 40 MG Oral         | NF                | 3             | Formulary Enhancement | N/A                                            |
| Xofluza (40 MG Dose) Tablet Therapy Pack 2 x 20 MG Oral         | 3                 | NF            | CMS Required Deletion | N/A                                            |
| Xofluza (80 MG Dose) Tablet Therapy Pack 2 x 40 MG Oral         | 3                 | NF            | CMS Required Deletion | N/A                                            |

2022

## Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

### 2022 FORMULARY CHANGES

| Drug Name                                                          | Current Drug Tier | New Drug Tier | Reason For Change     | Alternative Drug, Alternative Drug Tier |
|--------------------------------------------------------------------|-------------------|---------------|-----------------------|-----------------------------------------|
| <b>EFFECTIVE 01/01/2022 – ADDITIONS</b>                            |                   |               |                       |                                         |
| Cosentyx Solution Prefilled Syringe 75 MG/0.5ML Subcutaneous       | NF                | 5 + PA1       | Formulary Enhancement | N/A                                     |
| Dextroamphetamine Sulfate Tablet 15 MG Oral                        | NF                | 4 + QL 120    | Formulary Enhancement | N/A                                     |
| Dextroamphetamine Sulfate Tablet 20 MG Oral                        | NF                | 4 + QL 90     | Formulary Enhancement | N/A                                     |
| Dextroamphetamine Sulfate Tablet 30 MG Oral                        | NF                | 4 + QL 60     | Formulary Enhancement | N/A                                     |
| Difluprednate Emulsion 0.05 % Ophthalmic                           | NF                | 3             | Formulary Enhancement | N/A                                     |
| Nebivolol HCl Tablet 10 MG Oral                                    | NF                | 3             | Formulary Enhancement | N/A                                     |
| Nebivolol HCl Tablet 2.5 MG Oral                                   | NF                | 3             | Formulary Enhancement | N/A                                     |
| Nebivolol HCl Tablet 20 MG Oral                                    | NF                | 3             | Formulary Enhancement | N/A                                     |
| Nebivolol HCl Tablet 5 MG Oral                                     | NF                | 3             | Formulary Enhancement | N/A                                     |
| Panretin Gel 0.1 % External                                        | NF                | 5 + PA2       | Formulary Enhancement | N/A                                     |
| Truseltiq (100MG Daily Dose) Capsule Therapy Pack 100 MG Oral      | NF                | 5 + PA2       | Formulary Enhancement | N/A                                     |
| Truseltiq (125MG Daily Dose) Capsule Therapy Pack 100 & 25 MG Oral | NF                | 5 + PA2       | Formulary Enhancement | N/A                                     |
| Truseltiq (50MG Daily Dose) Capsule Therapy Pack 25 MG Oral        | NF                | 5 + PA2       | Formulary Enhancement | N/A                                     |
| Truseltiq (75MG Daily Dose) Capsule Therapy Pack 25 MG Oral        | NF                | 5 + PA2       | Formulary Enhancement | N/A                                     |
| Varenicline Tartrate Tablet 0.5 MG Oral                            | NF                | 3             | Formulary Enhancement | N/A                                     |
| Varenicline Tartrate Tablet 1 MG Oral                              | NF                | 3             | Formulary Enhancement | N/A                                     |
| Welireg Tablet 40 MG Oral                                          | NF                | 5 + PA2       | Formulary Enhancement | N/A                                     |
| Xofluza (80 MG Dose) Tablet Therapy Pack 1 x 80 MG Oral            | NF                | 3             | Formulary Enhancement | N/A                                     |
| <b>EFFECTIVE 02/01/2022</b>                                        |                   |               |                       |                                         |
| Adapalene Solution 0.1 % External                                  | 4                 | NF            | CMS Required Deletion | N/A                                     |
| azaTHIOprine Tablet 100 MG Oral                                    | NF                | 3 + BD        | Formulary Enhancement | N/A                                     |

2022

## Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

| 2022 FORMULARY CHANGES                                                  |                   |                 |                       |                                         |
|-------------------------------------------------------------------------|-------------------|-----------------|-----------------------|-----------------------------------------|
| Drug Name                                                               | Current Drug Tier | New Drug Tier   | Reason For Change     | Alternative Drug, Alternative Drug Tier |
| azaTHIOprine Tablet 75 MG Oral                                          | NF                | 3 + BD          | Formulary Enhancement | N/A                                     |
| Cyclafem 1/35 Tablet 1-35 MG-MCG Oral                                   | 2                 | NF              | CMS Required Deletion | N/A                                     |
| Cyclafem 7/7/7 Tablet 0.5/0.75/1-35 MG-MCG Oral                         | 2                 | NF              | CMS Required Deletion | N/A                                     |
| Everolimus Tablet 10 MG Oral                                            | NF                | 5 + QL 30 + PA2 | Formulary Enhancement | N/A                                     |
| Everolimus Tablet Soluble 2 MG Oral                                     | NF                | 5 + QL 30 + PA2 | Formulary Enhancement | N/A                                     |
| Everolimus Tablet Soluble 3 MG Oral                                     | NF                | 5 + QL 30 + PA2 | Formulary Enhancement | N/A                                     |
| Everolimus Tablet Soluble 5 MG Oral                                     | NF                | 5 + QL 60 + PA2 | Formulary Enhancement | N/A                                     |
| Invega Hafyera Suspension Prefilled Syringe 1092 MG/3.5ML Intramuscular | NF                | 5               | Formulary Enhancement | N/A                                     |
| Invega Hafyera Suspension Prefilled Syringe 1560 MG/5ML Intramuscular   | NF                | 5               | Formulary Enhancement | N/A                                     |
| Lybalvi Tablet 10-10 MG Oral                                            | NF                | 5               | Formulary Enhancement | N/A                                     |
| Lybalvi Tablet 15-10 MG Oral                                            | NF                | 5               | Formulary Enhancement | N/A                                     |
| Lybalvi Tablet 20-10 MG Oral                                            | NF                | 5               | Formulary Enhancement | N/A                                     |
| Lybalvi Tablet 5-10 MG Oral                                             | NF                | 5               | Formulary Enhancement | N/A                                     |
| Osmolex ER Tablet Extended Release 24 Hour 258 MG Oral                  | 4 + QL 30         | NF              | CMS Required Deletion | N/A                                     |
| PARoxetine HCl Suspension 10 MG/5ML Oral                                | NF                | 4               | Formulary Enhancement | N/A                                     |
| Pentacel Suspension Reconstituted Intramuscular                         | NF                | 3               | Formulary Enhancement | N/A                                     |
| Proparacaine HCl Solution 0.5 % Ophthalmic                              | 1                 | NF              | CMS Required Deletion | N/A                                     |
| Sertraline HCl Capsule 150 MG Oral                                      | NF                | 2               | Formulary Enhancement | N/A                                     |
| Sertraline HCl Capsule 200 MG Oral                                      | NF                | 2               | Formulary Enhancement | N/A                                     |
| Tavneos Capsule 10 MG Oral                                              | NF                | 5 + PA1         | Formulary Enhancement | N/A                                     |

## 2022 Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

| 2022 FORMULARY CHANGES                                         |                   |               |                       |                                         |
|----------------------------------------------------------------|-------------------|---------------|-----------------------|-----------------------------------------|
| Drug Name                                                      | Current Drug Tier | New Drug Tier | Reason For Change     | Alternative Drug, Alternative Drug Tier |
| Xpovio (100 MG Once Weekly) Tablet Therapy Pack 20 MG Oral     | 5 + PA2           | NF            | CMS Required Deletion | N/A                                     |
| Xpovio (40 MG Once Weekly) Tablet Therapy Pack 20 MG Oral      | 5 + PA2           | NF            | CMS Required Deletion | N/A                                     |
| Xpovio (40 MG Twice Weekly) Tablet Therapy Pack 20 MG Oral     | 5 + PA2           | NF            | CMS Required Deletion | N/A                                     |
| Xpovio (60 MG Once Weekly) Tablet Therapy Pack 20 MG Oral      | 5 + PA2           | NF            | CMS Required Deletion | N/A                                     |
| Xpovio (80 MG Once Weekly) Tablet Therapy Pack 20 MG Oral      | 5 + PA2           | NF            | CMS Required Deletion | N/A                                     |
| <b>EFFECTIVE 03/01/2022</b>                                    |                   |               |                       |                                         |
| Besremi Solution Prefilled Syringe 500 MCG/ML Subcutaneous     | NF                | 5 + PA2       | Formulary Enhancement | N/A                                     |
| Dupixent Solution Prefilled Syringe 100 MG/0.67ML Subcutaneous | NF                | 5 + PA1       | Formulary Enhancement | N/A                                     |
| Eprontia Solution 25 MG/ML Oral                                | NF                | 3             | Formulary Enhancement | N/A                                     |
| Everolimus Tablet 1 MG Oral                                    | NF                | 5 + BD        | Formulary Enhancement | N/A                                     |
| Exkivity Capsule 40 MG Oral                                    | NF                | 5 + PA2       | Formulary Enhancement | N/A                                     |
| Ezetimibe-Rosuvastatin Tablet 10-10 MG Oral                    | NF                | 3             | Formulary Enhancement | N/A                                     |
| Ezetimibe-Rosuvastatin Tablet 10-20 MG Oral                    | NF                | 3             | Formulary Enhancement | N/A                                     |
| Ezetimibe-Rosuvastatin Tablet 10-40 MG Oral                    | NF                | 3             | Formulary Enhancement | N/A                                     |
| Ezetimibe-Rosuvastatin Tablet 10-5 MG Oral                     | NF                | 3             | Formulary Enhancement | N/A                                     |
| Hydroxychloroquine Sulfate Tablet 100 MG Oral                  | NF                | 2             | Formulary Enhancement | N/A                                     |
| Hydroxychloroquine Sulfate Tablet 300 MG Oral                  | NF                | 2             | Formulary Enhancement | N/A                                     |
| Hydroxychloroquine Sulfate Tablet 400 MG Oral                  | NF                | 2             | Formulary Enhancement | N/A                                     |



2022

## Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

### 2022 FORMULARY CHANGES

| Drug Name                                                        | Current Drug Tier | New Drug Tier    | Reason For Change     | Alternative Drug, Alternative Drug Tier |
|------------------------------------------------------------------|-------------------|------------------|-----------------------|-----------------------------------------|
| Ivermectin TABLET 3 MG ORAL                                      | 2                 | 2 + PA2          | Formulary Update      | N/A                                     |
| Ketoprofen Capsule 50 MG Oral                                    | 2                 | NF               | CMS Required Deletion | N/A                                     |
| Livmarli Solution 9.5 MG/ML Oral                                 | NF                | 5 + PA1          | Formulary Enhancement | N/A                                     |
| Livtency Tablet 200 MG Oral                                      | NF                | 5 + PA1          | Formulary Enhancement | N/A                                     |
| Morphine Sulfate ER Capsule Extended Release 24 Hour 40 MG Oral  | 4 + QL 60         | NF               | CMS Required Deletion | N/A                                     |
| Naloxone HCl Liquid 4 MG/0.1ML Nasal                             | NF                | 3                | Formulary Enhancement | N/A                                     |
| Nylia 1/35 Tablet 1-35 MG-MCG Oral                               | NF                | 2                | Formulary Enhancement | N/A                                     |
| Picato Gel 0.015 % External                                      | 4                 | NF               | CMS Required Deletion | N/A                                     |
| Picato Gel 0.05 % External                                       | 4                 | NF               | CMS Required Deletion | N/A                                     |
| Scemblix Tablet 20 MG Oral                                       | NF                | 5 + QL 60 + PA2  | Formulary Enhancement | N/A                                     |
| Scemblix Tablet 40 MG Oral                                       | NF                | 5 + QL 300 + PA2 | Formulary Enhancement | N/A                                     |
| Ticovac Suspension Prefilled Syringe 2.4 MCG/0.5ML Intramuscular | NF                | 3                | Formulary Enhancement | N/A                                     |
| Vancomycin HCl Solution Reconstituted 250 MG Intravenous         | 4                 | NF               | CMS Required Deletion | N/A                                     |
| Zarah Tablet 3-0.03 MG Oral                                      | 2                 | NF               | CMS Required Deletion | N/A                                     |
| <b>EFFECTIVE 04/01/2022</b>                                      |                   |                  |                       |                                         |
| Accutane Capsule 10 MG Oral                                      | NF                | 4                | Formulary Enhancement | N/A                                     |
| Biktarvy Tablet 30-120-15 MG Oral                                | NF                | 5 + QL 30        | Formulary Enhancement | N/A                                     |
| Brimonidine Tartrate-Timolol Solution 0.2-0.5 % Ophthalmic       | NF                | 3                | Formulary Enhancement | N/A                                     |
| Bylvay (Pellets) Capsule Sprinkle 200 MCG Oral                   | NF                | 5 + PA1          | Formulary Enhancement | N/A                                     |
| Bylvay Capsule 1200 MCG Oral                                     | NF                | 5 + PA1          | Formulary Enhancement | N/A                                     |
| Bylvay Capsule 400 MCG Oral                                      | NF                | 5 + PA1          | Formulary Enhancement | N/A                                     |
| Desogestrel-Ethinyl Estradiol Tablet 0.15-30 MG-MCG Oral         | NF                | 2                | Formulary Enhancement | N/A                                     |

## 2022 Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

| 2022 FORMULARY CHANGES                                    |                   |               |                       |                                         |
|-----------------------------------------------------------|-------------------|---------------|-----------------------|-----------------------------------------|
| Drug Name                                                 | Current Drug Tier | New Drug Tier | Reason For Change     | Alternative Drug, Alternative Drug Tier |
| Hepatamine Solution 8 % Intravenous                       | 4 + BD            | NF            | CMS Required Deletion | N/A                                     |
| Intron A Solution 10000000 UNIT/ML Injection              | 5 + BD            | NF            | CMS Required Deletion | N/A                                     |
| Intron A Solution 6000000 UNIT/ML Injection               | 5 + BD            | NF            | CMS Required Deletion | N/A                                     |
| Ketoprofen Capsule 75 MG Oral                             | 2                 | NF            | CMS Required Deletion | N/A                                     |
| Oravig Tablet 50 MG Buccal                                | 3                 | NF            | CMS Required Deletion | N/A                                     |
| Tri-Previfem Tablet 0.18/0.215/0.25 MG-35 MCG Oral        | 2                 | NF            | CMS Required Deletion | N/A                                     |
| VariZIG Solution 125 UNIT/1.2ML Intramuscular             | 4                 | NF            | CMS Required Deletion | N/A                                     |
| <b>EFFECTIVE 05/01/2022</b>                               |                   |               |                       |                                         |
| Adapalene Gel 0.1 % External                              | 4                 | NF            | CMS Required Deletion | N/A                                     |
| Aminosyn-PF Solution 7 % Intravenous                      | 4 + BD            | NF            | CMS Required Deletion | N/A                                     |
| amLODIPine-Valsartan-HCTZ Tablet 10-160-12.5 MG Oral      | 1                 | NF            | CMS Required Deletion | N/A                                     |
| amLODIPine-Valsartan-HCTZ Tablet 10-160-25 MG Oral        | 1                 | NF            | CMS Required Deletion | N/A                                     |
| amLODIPine-Valsartan-HCTZ Tablet 10-320-25 MG Oral        | 1                 | NF            | CMS Required Deletion | N/A                                     |
| amLODIPine-Valsartan-HCTZ Tablet 5-160-12.5 MG Oral       | 1                 | NF            | CMS Required Deletion | N/A                                     |
| amLODIPine-Valsartan-HCTZ Tablet 5-160-25 MG Oral         | 1                 | NF            | CMS Required Deletion | N/A                                     |
| Blephamide Suspension 10-0.2 % Ophthalmic                 | 3                 | NF            | CMS Required Deletion | N/A                                     |
| Carglumic Acid Tablet 200 MG Oral                         | NF                | 5             | Formulary Enhancement | N/A                                     |
| Cefuroxime Sodium Solution Reconstituted 7.5 GM Injection | 4                 | NF            | CMS Required Deletion | N/A                                     |
| Citalopram Hydrobromide Capsule 30 MG Oral                | NF                | 2             | Formulary Enhancement | N/A                                     |



2022

## Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

### 2022 FORMULARY CHANGES

| Drug Name                                                      | Current Drug Tier | New Drug Tier   | Reason For Change     | Alternative Drug, Alternative Drug Tier |
|----------------------------------------------------------------|-------------------|-----------------|-----------------------|-----------------------------------------|
| Maraviroc Tablet 150 MG Oral                                   | NF                | 3 + QL 240      | Formulary Enhancement | N/A                                     |
| Maraviroc Tablet 300 MG Oral                                   | NF                | 3 + QL 120      | Formulary Enhancement | N/A                                     |
| Mavyret Packet 50-20 MG Oral                                   | NF                | 5 + PA1         | Formulary Enhancement | N/A                                     |
| Moxeza Solution 0.5 % Ophthalmic                               | 3                 | NF              | CMS Required Deletion | N/A                                     |
| OxyCODONE HCl ER Tablet ER 12 Hour Abuse-Deterrent 15 MG Oral  | 4 + QL 60         | NF              | CMS Required Deletion | N/A                                     |
| OxyCODONE HCl ER Tablet ER 12 Hour Abuse-Deterrent 30 MG Oral  | 4 + QL 60         | NF              | CMS Required Deletion | N/A                                     |
| OxyCODONE HCl ER Tablet ER 12 Hour Abuse-Deterrent 60 MG Oral  | 4 + QL 60         | NF              | CMS Required Deletion | N/A                                     |
| Rinvoq Tablet Extended Release 24 Hour 30 MG Oral              | NF                | 5 + PA1         | Formulary Enhancement | N/A                                     |
| Talzenna Capsule 0.5 MG Oral                                   | NF                | 5 + QL 30 + PA2 | Formulary Enhancement | N/A                                     |
| Talzenna Capsule 0.75 MG Oral                                  | NF                | 5 + QL 30 + PA2 | Formulary Enhancement | N/A                                     |
| Xarelto Suspension Reconstituted 1 MG/ML Oral                  | NF                | 3               | Formulary Enhancement | N/A                                     |
| <b>EFFECTIVE 06/01/2022</b>                                    |                   |                 |                       |                                         |
| Aztreonam Solution Reconstituted 2 GM Injection                | NF                | 4               | Formulary Enhancement | N/A                                     |
| Betaine Powder Oral                                            | NF                | 5               | Formulary Enhancement | N/A                                     |
| Farydak Capsule 10 MG Oral                                     | 5 + PA2           | NF              | CMS Required Deletion | N/A                                     |
| Farydak Capsule 15 MG Oral                                     | 5 + PA2           | NF              | CMS Required Deletion | N/A                                     |
| Farydak Capsule 20 MG Oral                                     | 5 + PA2           | NF              | CMS Required Deletion | N/A                                     |
| Fluoroplex Cream 1 % External                                  | 4                 | NF              | CMS Required Deletion | N/A                                     |
| GaviLyte-N with Flavor Pack SOLUTION RECONSTITUTED 420 GM ORAL | 1                 | NF              | CMS Required Deletion | N/A                                     |
| Invirase Tablet 500 MG Oral                                    | 5 + QL 120        | NF              | CMS Required Deletion | N/A                                     |
| Kinrix Suspension Intramuscular                                | 3                 | NF              | CMS Required Deletion | N/A                                     |
| Lacosamide Tablet 100 MG Oral                                  | NF                | 4               | Formulary Enhancement | N/A                                     |

2022

## Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

### 2022 FORMULARY CHANGES

| Drug Name                                                          | Current Drug Tier | New Drug Tier      | Reason For Change     | Alternative Drug, Alternative Drug Tier |
|--------------------------------------------------------------------|-------------------|--------------------|-----------------------|-----------------------------------------|
| Lacosamide Tablet 150 MG Oral                                      | NF                | 4                  | Formulary Enhancement | N/A                                     |
| Lacosamide Tablet 200 MG Oral                                      | NF                | 4                  | Formulary Enhancement | N/A                                     |
| Lacosamide Tablet 50 MG Oral                                       | NF                | 4                  | Formulary Enhancement | N/A                                     |
| Lenalidomide Capsule 10 MG Oral                                    | NF                | 5 + PA2            | Formulary Enhancement | N/A                                     |
| Lenalidomide Capsule 15 MG Oral                                    | NF                | 5 + PA2            | Formulary Enhancement | N/A                                     |
| Lenalidomide Capsule 25 MG Oral                                    | NF                | 5 + PA2            | Formulary Enhancement | N/A                                     |
| Lenalidomide Capsule 5 MG Oral                                     | NF                | 5 + PA2            | Formulary Enhancement | N/A                                     |
| Phexxi Gel 1.8-1-0.4 % Vaginal                                     | NF                | 4                  | Formulary Enhancement | N/A                                     |
| Pyrukynd Tablet 20 MG Oral                                         | NF                | 5 + QL 56/28 + PA1 | Formulary Enhancement | N/A                                     |
| Pyrukynd Tablet 5 MG Oral                                          | NF                | 5 + QL 56/28 + PA1 | Formulary Enhancement | N/A                                     |
| Pyrukynd Tablet 50 MG Oral                                         | NF                | 5 + QL 56/28 + PA1 | Formulary Enhancement | N/A                                     |
| Pyrukynd Taper Pack Tablet Therapy Pack 5 MG Oral                  | NF                | 5 + QL 7/7 + PA1   | Formulary Enhancement | N/A                                     |
| Pyrukynd Taper Pack Tablet Therapy Pack 7 x 20 MG & 7 x 5 MG Oral  | NF                | 5 + QL 14/14 + PA1 | Formulary Enhancement | N/A                                     |
| Pyrukynd Taper Pack Tablet Therapy Pack 7 x 50 MG & 7 x 20 MG Oral | NF                | 5 + QL 14/14 + PA1 | Formulary Enhancement | N/A                                     |
| Quadracel Suspension Intramuscular (58 UNT/ML)                     | NF                | 3                  | Formulary Enhancement | N/A                                     |
| Tekturna HCT Tablet 150-12.5 MG Oral                               | 3                 | NF                 | CMS Required Deletion | N/A                                     |
| Tekturna HCT Tablet 150-25 MG Oral                                 | 3                 | NF                 | CMS Required Deletion | N/A                                     |
| Temixys Tablet 300-300 MG Oral                                     | 5 + QL 30         | NF                 | CMS Required Deletion | N/A                                     |
| <b>EFFECTIVE 07/01/2022</b>                                        |                   |                    |                       |                                         |
| cycloSPORINE Emulsion 0.05 % Ophthalmic                            | NF                | 3 + QL 60          | Formulary Enhancement | N/A                                     |
| Deferiprone Tablet 1000 MG Oral                                    | NF                | 5                  | Formulary Enhancement | N/A                                     |
| Dexlansoprazole Capsule Delayed Release 30 MG Oral                 | NF                | 3 + QL 30          | Formulary Enhancement | N/A                                     |

2022

## Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

### 2022 FORMULARY CHANGES

| Drug Name                                                                                | Current Drug Tier | New Drug Tier | Reason For Change     | Alternative Drug, Alternative Drug Tier |
|------------------------------------------------------------------------------------------|-------------------|---------------|-----------------------|-----------------------------------------|
| Dexlansoprazole Capsule Delayed Release 60 MG Oral                                       | NF                | 3 + QL 30     | Formulary Enhancement | N/A                                     |
| Lithium Solution 8 MEQ/5ML Oral                                                          | 1                 | NF            | CMS Required Deletion | N/A                                     |
| Ozempic (1 MG/DOSE) Solution Pen-Injector 2 MG/1.5ML Subcutaneous                        | 3                 | NF            | CMS Required Deletion | N/A                                     |
| Ozempic (2 MG/DOSE) Solution Pen-Injector 8 MG/3ML Subcutaneous                          | NF                | 3             | Formulary Enhancement | N/A                                     |
| PreHevbrio Suspension 10 MCG/ML Intramuscular                                            | NF                | 3 + BD        | Formulary Enhancement | N/A                                     |
| Previfem Tablet 0.25-35 MG-MCG Oral                                                      | 2                 | NF            | CMS Required Deletion | N/A                                     |
| Rinvoq Tablet Extended Release 24 Hour 45 MG Oral                                        | NF                | 5 + PA1       | Formulary Enhancement | N/A                                     |
| Triumeq PD Tablet Soluble 60-5-30 MG Oral                                                | NF                | 5 + QL 180    | Formulary Enhancement | N/A                                     |
| Varenicline Tartrate 0.5 MG X 11 & 1 MG X 42 Oral                                        | NF                | 3             | Formulary Enhancement | N/A                                     |
| Zimhi Solution Prefilled Syringe 5 MG/0.5ML Injection                                    | NF                | 3             | Formulary Enhancement | N/A                                     |
| <b>EFFECTIVE 08/01/2022</b>                                                              |                   |               |                       |                                         |
| Abacavir-lamivudine-Zidovudine Tablet 300-150-300 MG Oral                                | 5 + QL 60         | NF            | CMS Required Deletion | N/A                                     |
| Chantix Continuing Month Pak Tablet 1 MG Oral                                            | 3                 | NF            | CMS Required Deletion | N/A                                     |
| Chantix Starting Month Pak Tablet 0.5 MG X 11 & 1 MG X 42 Oral                           | 3                 | NF            | CMS Required Deletion | N/A                                     |
| Chantix Tablet 0.5 MG Oral                                                               | 3                 | NF            | CMS Required Deletion | N/A                                     |
| Chantix Tablet 1 MG Oral                                                                 | 3                 | NF            | CMS Required Deletion | N/A                                     |
| Chlorzoxazone Tablet 250 MG Oral                                                         | NF                | 3             | Formulary Enhancement | N/A                                     |
| Fluticasone Furoate-Vilanterol Aerosol Powder Breath Activated 100-25 MCG/INH Inhalation | NF                | 4             | Formulary Enhancement | N/A                                     |

2022

## Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

| 2022 FORMULARY CHANGES                                                                   |                   |                 |                       |                                         |
|------------------------------------------------------------------------------------------|-------------------|-----------------|-----------------------|-----------------------------------------|
| Drug Name                                                                                | Current Drug Tier | New Drug Tier   | Reason For Change     | Alternative Drug, Alternative Drug Tier |
| Fluticasone Furoate-Vilanterol Aerosol Powder Breath Activated 200-25 MCG/INH Inhalation | NF                | 4               | Formulary Enhancement | N/A                                     |
| Fluticasone Propionate HFA Aerosol 110 MCG/ACT Inhalation                                | NF                | 3               | Formulary Enhancement | N/A                                     |
| Fluticasone Propionate HFA Aerosol 220 MCG/ACT Inhalation                                | NF                | 3               | Formulary Enhancement | N/A                                     |
| Fluticasone Propionate HFA Aerosol 44 MCG/ACT Inhalation                                 | NF                | 3               | Formulary Enhancement | N/A                                     |
| Isosorb Dinitrate-hydrALAZINE Tablet 20-37.5 MG Oral                                     | NF                | 3               | Formulary Enhancement | N/A                                     |
| Lacosamide Solution 10 MG/ML Oral                                                        | NF                | 4               | Formulary Enhancement | N/A                                     |
| Nizatidine Solution 15 MG/ML Oral                                                        | 2                 | NF              | CMS Required Deletion | N/A                                     |
| Ondansetron HCl Tablet 24 MG Oral                                                        | 1 + BD            | NF              | CMS Required Deletion | N/A                                     |
| oxyCODONE-Acetaminophen Solution 5-325 MG/5ML Oral                                       | NF                | 3 + QL 1080     | Formulary Enhancement | N/A                                     |
| Pirfenidone Tablet 267 MG Oral                                                           | NF                | 5 + PA1         | Formulary Enhancement | N/A                                     |
| Pirfenidone Tablet 801 MG Oral                                                           | NF                | 5 + PA1         | Formulary Enhancement | N/A                                     |
| Trizivir Tablet 300-150-300 MG Oral                                                      | NF                | 5 + QL 60       | Formulary Enhancement | N/A                                     |
| Ukonig Tablet 200 MG Oral                                                                | 5 + PA2           | NF              | CMS Required Deletion | N/A                                     |
| Vonjo Capsule 100 MG Oral                                                                | NF                | 5 + PA2         | Formulary Enhancement | N/A                                     |
| <b>EFFECTIVE 09/01/2022</b>                                                              |                   |                 |                       |                                         |
| Bexarotene Gel 1 % External                                                              | NF                | 5 + PA2         | Formulary Enhancement | N/A                                     |
| Camzyos Capsule 10 MG Oral                                                               | NF                | 5 + QL 30 + PA1 | Formulary Enhancement | N/A                                     |
| Camzyos Capsule 15 MG Oral                                                               | NF                | 5 + QL 30 + PA1 | Formulary Enhancement | N/A                                     |
| Camzyos Capsule 2.5 MG Oral                                                              | NF                | 5 + QL 30 + PA1 | Formulary Enhancement | N/A                                     |
| Camzyos Capsule 5 MG Oral                                                                | NF                | 5 + QL 30 + PA1 | Formulary Enhancement | N/A                                     |

## 2022 Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

| 2022 FORMULARY CHANGES                                             |                   |                  |                       |                                         |
|--------------------------------------------------------------------|-------------------|------------------|-----------------------|-----------------------------------------|
| Drug Name                                                          | Current Drug Tier | New Drug Tier    | Reason For Change     | Alternative Drug, Alternative Drug Tier |
| Fesoterodine Fumarate ER Tablet Extended Release 24 Hour 4 MG Oral | NF                | 4                | Formulary Enhancement | N/A                                     |
| Fesoterodine Fumarate ER Tablet Extended Release 24 Hour 8 MG Oral | NF                | 4                | Formulary Enhancement | N/A                                     |
| Flutamide Capsule 125 MG Oral                                      | 1                 | NF               | CMS Required Deletion | N/A                                     |
| levOCARNitine Solution 1 GM/10ML Oral                              | 1 + BD            | 1                | Formulary Enhancement | N/A                                     |
| levOCARNitine Tablet 330 MG Oral                                   | 1 + BD            | 1                | Formulary Enhancement | N/A                                     |
| Mayzent Starter Pack Tablet Therapy Pack 0.25 MG Oral              | NF                | 4 + PA1          | Formulary Enhancement | N/A                                     |
| Mayzent Tablet 1 MG Oral                                           | NF                | 5 + PA1          | Formulary Enhancement | N/A                                     |
| Methyldopa Tablet 250 MG Oral                                      | 2                 | NF               | CMS Required Deletion | N/A                                     |
| Methyldopa Tablet 500 MG Oral                                      | 2                 | NF               | CMS Required Deletion | N/A                                     |
| Orsythia Tablet 0.1-20 MG-MCG Oral                                 | 2                 | NF               | CMS Required Deletion | N/A                                     |
| SORafenib Tosylate Tablet 200 MG Oral                              | NF                | 5 + QL 120 + PA2 | Formulary Enhancement | N/A                                     |
| Tekturna HCT Tablet 300-12.5 MG Oral                               | 3                 | NF               | CMS Required Deletion | N/A                                     |
| Tekturna HCT Tablet 300-25 MG Oral                                 | 3                 | NF               | CMS Required Deletion | N/A                                     |
| Vijoice Tablet Therapy Pack 125 MG Oral                            | NF                | 5 + PA1          | Formulary Enhancement | N/A                                     |
| Vijoice Tablet Therapy Pack 200 & 50 MG Oral                       | NF                | 5 + PA1          | Formulary Enhancement | N/A                                     |
| Vijoice Tablet Therapy Pack 50 MG Oral                             | NF                | 5 + PA1          | Formulary Enhancement | N/A                                     |
| Vilazodone HCl Tablet 10 MG Oral                                   | NF                | 3                | Formulary Enhancement | N/A                                     |
| Vilazodone HCl Tablet 20 MG Oral                                   | NF                | 3                | Formulary Enhancement | N/A                                     |
| Vilazodone HCl Tablet 40 MG Oral                                   | NF                | 3                | Formulary Enhancement | N/A                                     |
| <b>EFFECTIVE 10/01/2022</b>                                        |                   |                  |                       |                                         |
| Caziant TABLET 0.1/0.125/0.15 -0.025 MG Oral                       | 2                 | NF               | CMS Required Deletion | N/A                                     |
| Digox Tablet 125 MCG Oral                                          | 1                 | NF               | CMS Required Deletion | N/A                                     |
| Digox Tablet 250 MCG Oral                                          | 1                 | NF               | CMS Required Deletion | N/A                                     |
| Na Sulfate-K Sulfate-Mg Sulf Solution 17.5-3.13-1.6 GM/177ML Oral  | NF                | 3                | Formulary Enhancement | N/A                                     |



2022

## Formulary Addendum

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

### 2022 FORMULARY CHANGES

| Drug Name                                                         | Current Drug Tier | New Drug Tier   | Reason For Change     | Alternative Drug, Alternative Drug Tier |
|-------------------------------------------------------------------|-------------------|-----------------|-----------------------|-----------------------------------------|
| Nucala Solution Prefilled Syringe 40 MG/0.4ML Subcutaneous        | NF                | 5 + PA1         | Formulary Enhancement | N/A                                     |
| Priorix Suspension Reconstituted Subcutaneous                     | NF                | 3               | Formulary Enhancement | N/A                                     |
| Ticovac Suspension Prefilled Syringe 1.2 MCG/0.25ML Intramuscular | NF                | 3               | Formulary Enhancement | N/A                                     |
| <b>EFFECTIVE 11/01/2022</b>                                       |                   |                 |                       |                                         |
| Lindane Shampoo 1 % External                                      | 4                 | NF              | CMS Required Deletion | N/A                                     |
| Procalamine Solution 3 % Intravenous                              | 3 + BD            | NF              | CMS Required Deletion | N/A                                     |
| Quadracel Suspension Prefilled Syringe 0.5 ML Intramuscular       | NF                | 3               | Formulary Enhancement | N/A                                     |
| Skyrizi Solution Cartridge 360 MG/2.4ML Subcutaneous              | NF                | 5 + PA1         | Formulary Enhancement | N/A                                     |
| <b>EFFECTIVE 12/01/2022</b>                                       |                   |                 |                       |                                         |
| Calquence Tablet 100 MG Oral                                      | NF                | 5 + QL 60 + PA2 | Formulary Enhancement | N/A                                     |
| Caplyta Capsule 10.5 MG Oral                                      | NF                | 5               | Formulary Enhancement | N/A                                     |
| Caplyta Capsule 21 MG Oral                                        | NF                | 5               | Formulary Enhancement | N/A                                     |
| Dabigatran Etxilate Mesylate Capsule 150 MG Oral                  | NF                | 4               | Formulary Enhancement | N/A                                     |
| Dabigatran Etxilate Mesylate Capsule 75 MG Oral                   | NF                | 4               | Formulary Enhancement | N/A                                     |
| Enbrel Solution Reconstituted 25 MG Subcutaneous                  | 5 + PA2           | NF              | CMS Required Deletion | N/A                                     |
| Hyftor Gel 0.2 % External                                         | NF                | 4 + PA1         | Formulary Enhancement | N/A                                     |
| Icosapent Ethyl Capsule 0.5 GM Oral                               | NF                | 4               | Formulary Enhancement | N/A                                     |
| Imbruvica Suspension 70 MG/ML Oral                                | NF                | 5 + PA2         | Formulary Enhancement | N/A                                     |
| Intron A Solution Reconstituted 18000000 UNIT Injection           | 5 + BD            | NF              | CMS Required Deletion | N/A                                     |
| Larissia Tablet 0.1-20 MG-MCG Oral                                | 2                 | NF              | CMS Required Deletion | N/A                                     |
| Lenalidomide Capsule 2.5 MG Oral                                  | NF                | 5 + PA2         | Formulary Enhancement | N/A                                     |



**2022**  
**Formulary Addendum**

BD - Part B vs. Part D, LA - This prescription may be available only at certain pharmacies, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 days

| <b>2022 FORMULARY CHANGES</b>                                         |                          |                      |                          |                                                |
|-----------------------------------------------------------------------|--------------------------|----------------------|--------------------------|------------------------------------------------|
| <b>Drug Name</b>                                                      | <b>Current Drug Tier</b> | <b>New Drug Tier</b> | <b>Reason For Change</b> | <b>Alternative Drug, Alternative Drug Tier</b> |
| Lenalidomide Capsule 20 MG Oral                                       | NF                       | 5 + PA2              | Formulary Enhancement    | N/A                                            |
| Norethindron-Ethinyl Estrad-Fe Tablet 1-20/1-30/1-35 MG-MCG Oral      | NF                       | 2                    | Formulary Enhancement    | N/A                                            |
| ProAir HFA Aerosol Solution 108 (90 Base) MCG/ACT Inhalation          | 3                        | NF                   | CMS Required Deletion    | N/A                                            |
| Tazarotene Gel 0.05 % External                                        | NF                       | 4                    | Formulary Enhancement    | N/A                                            |
| Tazarotene Gel 0.1 % External                                         | NF                       | 4                    | Formulary Enhancement    | N/A                                            |
| Venlafaxine Besylate ER Tablet Extended Release 24 Hour 112.5 MG Oral | NF                       | 2                    | Formulary Enhancement    | N/A                                            |

**Care N' Care (HMO/PPO)** will continue to cover the drugs in question for enrollees taking the drug at the time of change for the remainder of the plan year as long as the drug continues to be medically necessary and prescribed by the member's physician and was not removed for safety reasons.

If we remove drugs from our formulary, or add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost-sharing tier, you may ask **Care N' Care (HMO/PPO)** to make an exception to our coverage rules. To request a formulary, tiering or utilization restriction exception, please contact the Customer Experience Team at 1-877-374-7993 or, for TTY users, 711, October 1 – March 31, seven (7) days a week/8 a.m. – 8 p.m. (CST), or April 1 – September 30, Monday through Friday, 8 a.m. – 8 p.m. (CST).

This information is available for free in other languages. Please contact the Customer Experience Team at 1-877-374-7993 for additional information.

Esta información está disponible de forma gratuita en otros idiomas. Por favor de contactar nuestro número de servicio al cliente al 1-877-374-7993 para obtener información adicional

Beneficiaries must use network pharmacies to access their prescription drug benefit. Benefits, premium, and/or copayments/coinsurance may change on January 1 of each year. This information is not a complete description of benefits. Contact the plan for more information. Limitations, copayments, and restrictions may apply.

**2022**  
***Formulary Addendum***

---

Care N' Care is an HMO and PPO plan with a Medicare contract. Enrollment in Care N' Care depends on contract renewal.